Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 71.4% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,662 shares of the biopharmaceutical company’s stock after selling 24,083 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Regeneron Pharmaceuticals were worth $5,288,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in REGN. Vanguard Group Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 1.3% during the first quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company’s stock valued at $5,966,767,000 after buying an additional 121,545 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Regeneron Pharmaceuticals by 4.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company’s stock valued at $1,379,467,000 after buying an additional 89,579 shares during the last quarter. Amundi grew its holdings in shares of Regeneron Pharmaceuticals by 3.4% during the first quarter. Amundi now owns 1,603,901 shares of the biopharmaceutical company’s stock valued at $979,794,000 after buying an additional 52,166 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 18.0% during the first quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company’s stock valued at $724,984,000 after buying an additional 174,056 shares during the last quarter. Finally, GAMMA Investing LLC grew its holdings in shares of Regeneron Pharmaceuticals by 89,825.0% during the first quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company’s stock valued at $517,291,000 after buying an additional 814,713 shares during the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Up 1.6%

Shares of Regeneron Pharmaceuticals stock opened at $576.98 on Thursday. The firm has a 50-day simple moving average of $569.25 and a two-hundred day simple moving average of $573.47. The company has a market cap of $61.15 billion, a P/E ratio of 14.54, a price-to-earnings-growth ratio of 1.81 and a beta of 0.35. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $1,070.00. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping analysts’ consensus estimates of $8.43 by $4.46. The business had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company’s revenue was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $11.56 earnings per share. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were given a $0.88 dividend. The ex-dividend date was Monday, August 18th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is 8.87%.

Analysts Set New Price Targets

REGN has been the topic of a number of research analyst reports. Guggenheim boosted their price objective on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the company a “buy” rating in a report on Friday, August 1st. Argus lowered shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, June 30th. Jefferies Financial Group upped their price target on shares of Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a report on Wednesday, August 27th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $850.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, July 23rd. Finally, Redburn Atlantic raised Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Thursday, August 14th. Three analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $817.67.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.